Insider Selling: Revolution Medicines (NASDAQ:RVMD) CFO Sells 2,753 Shares of Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 2,753 shares of Revolution Medicines stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $273,868.44. Following the completion of the sale, the chief financial officer owned 125,512 shares in the company, valued at approximately $12,485,933.76. This represents a 2.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Jack Anders also recently made the following trade(s):

• On Wednesday, January 7th, Jack Anders sold 10,000 shares of Revolution Medicines stock. The shares were sold at an average price of $98.00, for a total value of $980,000.00.

Revolution Medicines Price Performance

RVMD stock traded up $1.18 on Thursday, hitting $99.29. 1,485,201 shares of the company’s stock traded hands, compared to its average volume of 2,335,170. The stock has a market cap of $19.68 billion, a price-to-earnings ratio of -16.80 and a beta of 0.99. Revolution Medicines, Inc. has a 1-year low of $29.17 and a 1-year high of $124.49. The stock has a fifty day moving average of $103.58 and a 200-day moving average of $76.24. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.16.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30). During the same period last year, the business earned ($1.12) EPS. On average, analysts forecast that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Indiana Trust & Investment Management Co bought a new position in Revolution Medicines in the 4th quarter valued at about $32,000. Global Retirement Partners LLC boosted its holdings in shares of Revolution Medicines by 1,002.8% during the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after acquiring an additional 361 shares during the period. Torren Management LLC acquired a new position in shares of Revolution Medicines in the fourth quarter valued at approximately $33,000. Arax Advisory Partners acquired a new position in shares of Revolution Medicines in the fourth quarter valued at approximately $38,000. Finally, GAMMA Investing LLC grew its holdings in Revolution Medicines by 45.1% in the 3rd quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock valued at $39,000 after buying an additional 260 shares in the last quarter. 94.34% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

RVMD has been the subject of a number of recent research reports. Evercore upgraded Revolution Medicines to a “strong-buy” rating in a research report on Wednesday, February 25th. Jefferies Financial Group began coverage on shares of Revolution Medicines in a report on Monday. They issued a “buy” rating on the stock. UBS Group assumed coverage on shares of Revolution Medicines in a report on Friday, February 27th. They set a “buy” rating for the company. Wedbush reiterated an “outperform” rating on shares of Revolution Medicines in a research report on Friday, January 9th. Finally, Benchmark reiterated an “overweight” rating on shares of Revolution Medicines in a report on Tuesday, February 17th. Four research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $78.94.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.